Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
Adult
Aged
Brain Neoplasms
/ enzymology
DNA Methylation
/ genetics
Disease Progression
Female
Glioblastoma
/ enzymology
Humans
Isocitrate Dehydrogenase
/ genetics
Kaplan-Meier Estimate
Male
Middle Aged
Multivariate Analysis
Mutation
/ genetics
Neoplasm Recurrence, Local
/ genetics
O(6)-Methylguanine-DNA Methyltransferase
/ genetics
Prognosis
Promoter Regions, Genetic
Retrospective Studies
Survival Analysis
Treatment Outcome
IDH status
MGMT
glioblastoma
overall survival
recurrent glioblastoma
Journal
Japanese journal of clinical oncology
ISSN: 1465-3621
Titre abrégé: Jpn J Clin Oncol
Pays: England
ID NLM: 0313225
Informations de publication
Date de publication:
01 Jan 2021
01 Jan 2021
Historique:
received:
19
04
2020
accepted:
19
08
2020
pubmed:
6
9
2020
medline:
15
1
2021
entrez:
5
9
2020
Statut:
ppublish
Résumé
Mutations in the isocitrate dehydrogenase (IDH)1 gene are favourable prognostic factors in newly diagnosed diffuse gliomas, whereas it remains controversial in the recurrent glioblastoma setting. A total of 171 patients with newly diagnosed glioblastoma, either 'primary' glioblastoma or 'secondary' glioblastoma, treated at Kyorin University Hospital or Japanese Red Cross Medical Center from 2000 to 2015 were included. Patients with confirmed IDH1 status and O6-methylguanine-DNA methyltransferase promoter methylation status were retrospectively analysed for overall survival from the initial diagnosis (n = 147) and after the first progression (n = 122). IDH1 mutation but not IDH2 was noted in 19 of 147 patients with glioblastoma (12.9%). In patients with 'primary' glioblastoma (n = 136), median overall survival after the first progression was 13.5 and 10.5 months for mutant IDH1 and wild-type IDH1 glioblastoma, respectively (P = 0.747). Multivariate analysis revealed O6-methylguanine-DNA methyltransferase promoter methylation, and Karnofsky Performance status 60 or higher, were independent prognostic factors for better overall survival after the first progression. When 'primary' glioblastoma and 'secondary' glioblastoma were combined, median overall survival from the first progression was not significantly different between the mutant IDH1 group (10.1 months) and wild-type IDH1 group (10.5 months) (P = 0.559), whereas median overall survival from the initial diagnosis was significantly different (47.5 months vs.18.3 months, respectively; P = 0.035). These results suggest that IDH1 mutation may not be a prognostic factor for survival at the first progression of patients with 'primary' glioblastoma and pretreated 'secondary' glioblastoma, and further warrant investigation in prospective studies.
Sections du résumé
BACKGROUNDS
BACKGROUND
Mutations in the isocitrate dehydrogenase (IDH)1 gene are favourable prognostic factors in newly diagnosed diffuse gliomas, whereas it remains controversial in the recurrent glioblastoma setting.
METHODS
METHODS
A total of 171 patients with newly diagnosed glioblastoma, either 'primary' glioblastoma or 'secondary' glioblastoma, treated at Kyorin University Hospital or Japanese Red Cross Medical Center from 2000 to 2015 were included. Patients with confirmed IDH1 status and O6-methylguanine-DNA methyltransferase promoter methylation status were retrospectively analysed for overall survival from the initial diagnosis (n = 147) and after the first progression (n = 122).
RESULTS
RESULTS
IDH1 mutation but not IDH2 was noted in 19 of 147 patients with glioblastoma (12.9%). In patients with 'primary' glioblastoma (n = 136), median overall survival after the first progression was 13.5 and 10.5 months for mutant IDH1 and wild-type IDH1 glioblastoma, respectively (P = 0.747). Multivariate analysis revealed O6-methylguanine-DNA methyltransferase promoter methylation, and Karnofsky Performance status 60 or higher, were independent prognostic factors for better overall survival after the first progression. When 'primary' glioblastoma and 'secondary' glioblastoma were combined, median overall survival from the first progression was not significantly different between the mutant IDH1 group (10.1 months) and wild-type IDH1 group (10.5 months) (P = 0.559), whereas median overall survival from the initial diagnosis was significantly different (47.5 months vs.18.3 months, respectively; P = 0.035).
CONCLUSIONS
CONCLUSIONS
These results suggest that IDH1 mutation may not be a prognostic factor for survival at the first progression of patients with 'primary' glioblastoma and pretreated 'secondary' glioblastoma, and further warrant investigation in prospective studies.
Identifiants
pubmed: 32888020
pii: 5901556
doi: 10.1093/jjco/hyaa162
pmc: PMC7767982
doi:
Substances chimiques
Isocitrate Dehydrogenase
EC 1.1.1.41
O(6)-Methylguanine-DNA Methyltransferase
EC 2.1.1.63
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
45-53Informations de copyright
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.
Références
Brain Tumor Pathol. 2013 Oct;30(4):224-32
pubmed: 23494632
J Neurooncol. 2016 Aug;129(1):147-54
pubmed: 27270908
Neuro Oncol. 2016 Nov;18(11):1529-1537
pubmed: 27370396
Lancet Oncol. 2016 Nov;17(11):1521-1532
pubmed: 27686946
Acta Neuropathol. 2008 Dec;116(6):597-602
pubmed: 18985363
Neuro Oncol. 2017 Feb 1;19(2):242-251
pubmed: 27571885
J Clin Oncol. 2014 Mar 10;32(8):783-90
pubmed: 24516018
J Neurooncol. 2009 Apr;92(2):227-32
pubmed: 19037596
Clin Cancer Res. 2009 Oct 1;15(19):6002-7
pubmed: 19755387
JAMA. 2015 Dec 15;314(23):2535-43
pubmed: 26670971
Acta Neuropathol. 2010 Dec;120(6):707-18
pubmed: 21088844
Cancer Res. 2016 Feb 1;76(3):525-34
pubmed: 26762204
Acta Neuropathol. 2020 Mar;139(3):603-608
pubmed: 31996992
J Clin Oncol. 2013 Nov 10;31(32):4085-91
pubmed: 24101040
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Neuro Oncol. 2009 Aug;11(4):341-7
pubmed: 19435942
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):623-30
pubmed: 20888136
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Science. 2008 Sep 26;321(5897):1807-12
pubmed: 18772396
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010